287 related articles for article (PubMed ID: 35742910)
1. The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.
Regazzo D; Mondin A; Scaroni C; Occhi G; Barbot M
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742910
[TBL] [Abstract][Full Text] [Related]
2. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
3. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
5. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Lasio G; Losa M
Neuroendocrinology; 2023; 113(6):606-614. PubMed ID: 36791678
[TBL] [Abstract][Full Text] [Related]
6. Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition.
Viho EMG; Kroon J; Feelders RA; Houtman R; van den Dungen ESR; Pereira AM; Hunt HJ; Hofland LJ; Meijer OC
J Endocrinol; 2023 Feb; 256(2):. PubMed ID: 36445262
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].
Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M
Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880
[TBL] [Abstract][Full Text] [Related]
8. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
9. Low level of glucocorticoid receptor messenger ribonucleic acid in pituitary adenomas manifesting Cushing's disease with resistance to a high dose-dexamethasone suppression test.
Mu YM; Takayanagi R; Imasaki K; Ohe K; Ikuyama S; Yanase T; Nawata H
Clin Endocrinol (Oxf); 1998 Sep; 49(3):301-6. PubMed ID: 9861319
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Ebisawa T; Tojo K; Tajima N; Kamio M; Oki Y; Ono K; Sasano H
Endocr Pathol; 2008; 19(4):252-60. PubMed ID: 19048413
[TBL] [Abstract][Full Text] [Related]
11. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
12. Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.
Teshima T; Matsumoto H; Okusa T; Nakamura Y; Koyama H
PLoS One; 2015; 10(8):e0135516. PubMed ID: 26262685
[TBL] [Abstract][Full Text] [Related]
13. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
14. A patient with recurrent hypercortisolism after removal of an ACTH-secreting pituitary adenoma due to an adrenal macronodule.
Timmers HJ; van Ginneken EM; Wesseling P; Sweep CG; Hermus AR
J Endocrinol Invest; 2006 Nov; 29(10):934-9. PubMed ID: 17185905
[TBL] [Abstract][Full Text] [Related]
15. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
16. Criteria of cure and remission in Cushing's disease: an update.
Czepielewski MA; Rollin GA; Casagrande A; Ferreira NP
Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1362-72. PubMed ID: 18209875
[TBL] [Abstract][Full Text] [Related]
17. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.
Suri D; Weiss RE
J Clin Endocrinol Metab; 2005 Mar; 90(3):1340-6. PubMed ID: 15585550
[TBL] [Abstract][Full Text] [Related]
18. Perioperative hypothalamic pituitary adrenal function in patients with silent corticotroph adenomas.
Cheres AF; ElAsmar N; Rajpal A; Selman WR; Arafah BM
Pituitary; 2017 Aug; 20(4):471-476. PubMed ID: 28528397
[TBL] [Abstract][Full Text] [Related]
19. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
